Adjuvant regional isolated perfusion with melphalan for patients with clark V melanoma of the extremities
Adjuvant regional isolated perfusion with melphalan for patients with clark V melanoma of the extremities
复制标题
四肢克拉克 V 型黑色素瘤患者的马法兰辅助局部隔离灌注
DOI：
10.1002/jso.2930520411
复制
发表时间：
1993
影响因子：
2.5
通讯作者：
H. Franklin
中科院分区：
文献类型：
--
作者：
B. Vrouenraets;B. Kroon;J. Klaase;Bert N. Van Gell;A. Eggermont;H. Franklin
1978年至1990年，对32例Clark V黑色素瘤患者采用马法兰广泛切除和辅助区域隔离灌注治疗。安德森分期：I期22例，IIIb期10例。5年生存率分别为58%和27%。7例复发[I期，2例，IIIb期，5例(P=0.03)]，17例中有4例发生区域淋巴结转移。在已知的预后变量中，只有原发灶溃烂显著影响生存率(P=0.03)。与文献中关于非血流灌注患者的数据相比，我们没有看到存活率有任何改善。在缺乏无血流灌注的Clark V黑色素瘤患者局部复发率的数据的情况下，我们不能说辅助灌注是否降低了这种风险。因此，EORTC/WHO对原发高危肢体黑色素瘤的前瞻性随机试验的结果还有待观察。©1993 Wiley-Liss，Inc.
From 1978 to 1990, 32 patients with Clark V melanoma were treated by wide excision of the primary and adjuvant regional isolated perfusion with melphalan. M.D. Anderson stage of disease was stage I in 22 and stage IIIb in 10 patients. Five‐year survival rates were 58% and 27%, respectively. Seven patients developed a recurrence in the perfused limb [stage I, 2, stage IIIb, 5 patients (P = 0.03)], and 4 of 17 patients developed regional lymph node metastases. Of the well‐known prognostic variables, only ulceration of the primary tumor significantly influenced survival (P = 0.03). We did not see any improvement in survival rates compared with literature data on nonperfused patients. In the absence of data on locoregional recurrence rates in nonperfused Clark V melanoma patients, we cannot say whether adjuvant perfusion diminished this risk. Therefore, the results of the prospective randomized EORTC/WHO trial in primary high‐risk extremity melanoma have to be awaited. © 1993 Wiley‐Liss, Inc.
DOI：
10.1001/archsurg.1987.01400180089017
发表时间：
1987
期刊：
Archives of surgery (Chicago, Ill. : 1960)
影响因子：
--
作者：
Schneebaum,S;Briele,HA;Walker,MJ;Greager,J;Wood,DK;Ronan,SG;Patel,MK;DasGupta,TK
通讯作者：
DasGupta,TK